Vitronectin receptor antagonist pharmaceuticals
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 22, 2008
Grant Date -
Jul 14, 2005
app pub date -
Feb 2, 2004
filing date -
Dec 18, 1998
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention describes novel compounds of the formula: (Q).sub.d-L.sub.n-C.sub.h, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 4 Citation Count
- C07D Class
- 21.95 % this patent is cited more than
- 17 Age
